Advanced Solid Tumor - BNT326-01

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT07070232

Location: Hartford Hospital

Contact: Hayley.Dunnack@hhchealth.org